ImmuPharma plc (LON:IMM – Get Free Report)’s stock price rose 42.2% on Monday . The stock traded as high as GBX 5.60 ($0.07) and last traded at GBX 5.60 ($0.07). Approximately 25,452,426 shares were traded during mid-day trading, an increase of 27% from the average daily volume of 20,003,797 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Stock Performance
The stock’s 50 day simple moving average is GBX 1.92 and its two-hundred day simple moving average is GBX 1.78. The firm has a market capitalization of £19.57 million, a PE ratio of -470.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Insider Buying Explained: What Investors Need to Know
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- How to Choose Top Rated Stocks
- What Does the Future Hold for Eli Lilly?
- Dividend Capture Strategy: What You Need to Know
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
